GBM Tumor Microenvironment Drug Target Atlas
Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…
GBM Tumor Microenvironment Drug Target Atlas
Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug programs focused on cancer cells alone.
Build an interactive atlas of glioblastoma tumor microenvironment components and their druggable interactions, specifically focused on non-tumor cells (astrocytes, microglia, oligodendrocyte precursors, pericytes, endothelial cells) and the signals they send to cancer cells. For each cell type, the atlas would catalog known pro-tumorigenic signaling pathways, available inhibitors (preclinical or clinical), dependence on specific GBM molecular subtypes (classical, proneural, mesenchymal), and key supporting references.
The atlas would include an interactive network visualization showing the web of crosstalk between different microenvironment cells and GBM tumor cells — with drug targets highlighted as clickable nodes showing what's available to block each interaction. A clinical trial integration module would show which microenvironment-targeted approaches are in active GBM trials.
GBM is almost universally fatal, with median survival under 15 months despite surgery, radiation, and temozolomide. Most drug programs target cancer cell-intrinsic pathways that fail because of heterogeneity and rapid adaptation. The emerging recognition that GBM co-opts its normal brain cell neighbors is creating a new target landscape. A structured atlas that maps these microenvironment interactions and their therapeutic tractability would be valuable for the GBM research community and for drug developers seeking differentiated entry points into this indication.
Who Is This For?
Neuro-oncology researchers studying GBM tumor biology, pharmaceutical companies developing GBM drugs, and clinical investigators designing microenvironment-targeting GBM trials.
Skills & Tools Needed
- Knowledge of GBM biology and brain cell types
- Biocuration of tumor microenvironment literature
- Interactive network visualization (Cytoscape.js or D3.js)
- Web database development
- ClinicalTrials.gov data integration
Feasibility
medium — Building an accurate, well-curated microenvironment atlas requires deep domain expertise in GBM biology and sustained curation effort, but the visualization and database infrastructure is technically straightforward.
Inspired by: Scientists find hidden brain cells helping deadly cancer grow
